をいずれか含む
  • 全て含む
  • いずれか含む
121976003

NCP candidate vaccines enter a・・・


このコンテンツは出版・報道コンテンツをご利用いただける
アカウントでログイン後に閲覧できます。
ご不明点はアフロカスタマーセンターまでお問い合わせ下さい。

ライトボックスに追加 カンプデータをダウンロードする 印刷

作品情報

作品番号
121976003
タイトル
NCP candidate vaccines enter animal testing phase
クレジット表記
動画:CCTV+/アフロ
日付
2020年2月9日
撮影国
中国
コンテンツカテゴリー
ニュース
ライセンスタイプ
RM(ライツマネージド)
モデルリリース
なし 
プロパティリリース
なし 
コーデック
H264
フレームレート
29.97 fps
長さ
127.69 秒
もっと見る

ストーリー

Since the outbreak of the novel coronavirus in China, scientists in various pharmaceutical companies and other institutions have tried to create a vaccine to stop its spread. Recently, a Shanghai company produced samples of a new vaccine which has just been tested on animals.

Animal testing is a must for any vaccine before it is put to clinical use. Researchers at Tongji University in Shanghai are using some healthy mice to test some of the latest vaccine samples against the novel coronavirus.

"The mouse testing is just a preliminary screening for candidate vaccines. After screening out effective antibodies against this virus, the candidate vaccine will continue to go through a toxicological test, which will need larger animals that are similar to human beings for safety test, such as machin. All of these should be done before applying for clinical testing," said Liu Zhongmin, president at the Shanghai East Hospital at Tongji University School of Medicine.

President Liu said over 100 mice will be needed to perform the test. After being injected, the mice will be labeled and taken care of in labs.

Scientists said it will take several days to see whether these mice will produce antibodies to prevent the virus.

To guarantee its objectivity, animal tests with the same vaccine samples are also conducted simultaneously at the Chinese Center for Disease Control and Prevention (CDC) and National Institutes for Food and Drug Control in Beijing.

"The mRNA-based vaccine technology is one of the world's most advanced and unique technologies to produce vaccine. It features a shorter preparation time and higher efficiency," said Liu.

Those vaccines are co-designed and developed by China CDC, Tongji University and a Shanghai vaccine company.

After getting the antigen from China's CDC in late January, the vaccine company spent two weeks producing these multiple types of m-RNA vaccine samples.

"We have prepared nine to 12 different antigens for the vaccine samples. If the animal test fails, we will continue to improve the formulation of the vaccines," said Li Hangwen, CEO of Stemirna Therapeutics, a high-tech biotechnology company.

To create an effective vaccine is never an easy job. At present, dozens of domestic and global companies and institutions have invested huge amounts of money and time in creating a vaccine for this novel coronavirus.

"Generally, a vaccine needs to pass three steps of clinical testing. The period of time may last from several months to several years based on the number of clinical tests and number of people who have taken the tests," said Li.

If the animal tests go well, Li hopes they can begin further clinical trials as early as April. Although people want a cure that ultimately ends the coronavirus epidemic soon, scientists said effective vaccines must undergo rigorous testing before being put to clinical use.

(Original Title: NCP candidate vaccines enter animal testing phase)
もっと見る

タイムライン

Shanghai Municipality, east China - Recent (CGTN - No access Chinese mainland)
1. Various of mice in box
2. Various of researchers at work
3. SOUNDBITE (Chinese) Liu Zhongmin, President, Shanghai East Hospital, Tongji University School of Medicine(partially overlaid with shot 4):
"The mouse testing is just a preliminary screening for candidate vaccines. After screening out effective antibodies against this virus, the candidate vaccine will continue to go through a toxicological test, which will need larger animals that are similar to human beings for safety test, such as machin. All of these should be done before applying for clinical testing."
++SHOT OVERLAYING SOUNDBITE++
4. Various of researchers at work, giving injection to mouse
++SHOT OVERLAYING SOUNDBITE++
5. Various of mice in box
6. Various of researchers at work
7. SOUNDBITE (Chinese) Liu Zhongmin, President, Shanghai East Hospital, Tongji University School of Medicine(starting with shot 6):
"The mRNA-based vaccine technology is one of the world's most advanced and unique technologies to produce vaccine. It features a shorter preparation time and higher efficiency."
8. Various of researchers at work
9. Centrifuge tubes
10. SOUNDBITE (Chinese) Li Hangwen, CEO, Stemirna Therapeutics (partially overlaid with shot 11):
"We have prepared nine to 12 different antigens for the vaccine samples. If the animal test fails, we will continue to improve the formulation of the vaccines."
++SHOT OVERLAYING SOUNDBITE++
11. Centrifuge tubes
++SHOT OVERLAYING SOUNDBITE++
12. Various of researchers at work
13. SOUNDBITE (Chinese) Li Hangwen, CEO, Stemirna Therapeutics (partially overlaid with shot 14):
"Generally, a vaccine needs to pass three steps of clinical testing. The period of time may last from several months to several years based on the number of clinical tests and number of people who have taken the tests."
++SHOT OVERLAYING SOUNDBITE++
14. Researcher at work
++SHOT OVERLAYING SOUNDBITE++
15. Various of researcher at work
もっと見る

サイズ

フレームサイズ
FullHD 1920 × 1080
形式
MP4

料金

プライスゾーン
Standard(料金案内)

ご利用上の注意

  • 被写体やご利用方法によっては、被写体管理者から事前に使用許可を得る必要がある場合があります。
  • 本作品を「出版・報道・教育目的以外」でご使用の際は、事前申請が必要です。
    媒体に関わらず営利目的使用をご希望の場合、お問合せください。
オンライン見積り
カートに入れる
アフロカスタマーセンター
営業時間<年中無休> 9:30~22:00
広告・販促・ウェブ
0120-565-410
sagasu@aflo.com
報道・出版・教育
0120-656-410
houdou@aflo.com
TV番組
0120-707-410
tv@aflo.com

キーワード

キーワードは画像や動画を検索するための便宜的なものであり、必ずしも画像や動画の内容を表すものではありません。
また、特定の思想やイメージを表すキーワードが付与されていても、そのキーワードと画像や動画の内容とを関連づける意図はないことにご留意ください。